Trebananib

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameTrebananib
Drug Alias Name曲巴那尼trebananibtrebananibum曲巴尼布Tovasanib +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionTEK receptor tyrosine kinase antagonistsAngiopoietin-1 inhibitorsAngiopoietin-2 inhibitors
TargetsAngiopoietin-2Angiopoietin-1TEK receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursRenal InsufficiencyKidney Diseases +[41] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteNational Cancer InstituteAmgen Inc
Inactive CompaniesRoswell Park Cancer InstituteUniversity Of Colorado DenverTakeda Pharmaceutical Co Ltd
Active IndicationsSolid tumoursBrain NeoplasmsOligodendroglioma +[5] 
Inactive IndicationsRenal InsufficiencyKidney DiseasesNeoplasm Metastasis +[36] 

Other Information

ATC CodeN/A
Related LinksKEGG